Schering-Plough Shareholders Support Merck Acquisition

Friday, August 07, 2009

More than 99 percent of shareholders of drugmaker Schering-Plough support being bought by bigger New Jersey neighbor Merck. The acquisition would make Merck the world's second-biggest drug maker by prescription medicine sales, just behind Pfizer. Barbara Ryan, a pharmaceutical industry analyst with Deutsche Bank, says the merger can help the companies reduce expenses – and compensate for a lack of new blockbuster drugs.

RYAN: Merck specifically would face a significant hole in its earnings in 2013 when it’s scheduled to lose exclusivity for one of their biggest drugs, Singulair.

Singulair is used to treat asthma and allergies. Ryan says many pharmaceutical companies are in a similar position of seeing their drugs go generic, setting off a large wave of acquisitions.


More in:

News, weather, Radiolab, Brian Lehrer and more.
Get the best of WNYC in your inbox, every morning.

Leave a Comment

Register for your own account so you can vote on comments, save your favorites, and more. Learn more.
Please stay on topic, be civil, and be brief.
Email addresses are never displayed, but they are required to confirm your comments. Names are displayed with all comments. We reserve the right to edit any comments posted on this site. Please read the Comment Guidelines before posting. By leaving a comment, you agree to New York Public Radio's Privacy Policy and Terms Of Use.


Latest Newscast




WNYC is supported by the Charles H. Revson Foundation: Because a great city needs an informed and engaged public


Supported by